| abstract |
By the method, competingl progesterone antagonists, includingthe two new steroid 11, 19-/4-(cyanophenyl)-O-phenylene/-17 hydroxy-17-(3-hydroxyprop-1(Z)-enyl-4-androstene-3-on and 11 ,19-/4-(3-pyridinyl)-O-phenylene/-17- - hydroxy-17-(3-hydroxyprop-1(Z)-enyl-4-androstene-3-on, which inhibit theformation of endometrial glands in doses smaller than the doseinhibiting their ovulation, and under the abortive dose, in thisway attaining oral contraception in women which has no adverseeffect on the menstrual cycle and creates no danger of abortionprovocation of an eariler implanted ovum or foetus. |